Derivative exercise or conversion — not an open-market buy.
Loading…
Traded Oct 15, 2025 · Filed Oct 17, 2025
Gilead Sciences's Chief Commercial Officer sold $354K of Gilead Sciences shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$354,240
Shares × reported transaction price
69 days after results of Aug 7, 2025, 15 days before results of Oct 30, 2025
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $118.30 on Oct 15, 2025, within 2% of its 52-week high, after a 5% rise over the previous 30 trading days
52-week range $86.29 (Oct 21, 2024) to $120.47 (Aug 11, 2025), 94% of the way up, from 250 adjusted closes. 30 trading days earlier: $112.99 on Sep 3, 2025. Describes the past only, not a forecast
A WARN layoff notice covering 17 workers was filed in California on November 12, 2025.
From the official state WARN list, 28 days after the trade. Shown for timing only; the two filings are separate
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | -1.5% | +1.9% | -3.5% |
| 30 days | +1.0% | +0.2% | +0.8% |
| 90 days | -1.3% | +4.2% | -5.5% |
| 180 days | +13.8% | +5.3% | +8.5% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
Officer sold ~$2.13M of Gilead Sciences
Scheduled in advanceDerivative exercise or conversion — not an open-market buy.